Duvelisib has marked response, survival benefit in difficult-to-treat leukemia and lymphoma
For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease outcomes, according to phase III trial data published today in the journal Blood.
Oct 4, 2018
0
1